Last reviewed · How we verify
Rifamycin SV MMX
Rifamycin SV MMX is a modified-release antibiotic that targets bacterial RNA polymerase to inhibit bacterial protein synthesis, with enhanced delivery to the colon.
Rifamycin SV MMX is a modified-release antibiotic that targets bacterial RNA polymerase to inhibit bacterial protein synthesis, with enhanced delivery to the colon. Used for Clostridioides difficile infection (CDI), Traveler's diarrhea.
At a glance
| Generic name | Rifamycin SV MMX |
|---|---|
| Also known as | Rifamycin, Aemcolo |
| Sponsor | RedHill Biopharma Limited |
| Drug class | Ansamycin antibiotic |
| Target | Bacterial RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Rifamycin SV is an ansamycin antibiotic that binds to bacterial RNA polymerase and blocks transcription. The MMX (Multi-Matrix system) formulation is an oral delivery technology designed to release the drug specifically in the colon, allowing high local concentrations while minimizing systemic absorption. This targeted approach is intended to treat gastrointestinal infections while reducing systemic side effects.
Approved indications
- Clostridioides difficile infection (CDI)
- Traveler's diarrhea
Common side effects
- Gastrointestinal disturbances
- Nausea
- Abdominal pain
- Diarrhea
Key clinical trials
- Rifamycin in Minimal Hepatic Encephalopathy (PHASE2)
- Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years (PHASE2)
- Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years (PHASE2)
- Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) (PHASE2)
- Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D (PHASE2)
- Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea (PHASE2)
- Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea (PHASE3)
- Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifamycin SV MMX CI brief — competitive landscape report
- Rifamycin SV MMX updates RSS · CI watch RSS
- RedHill Biopharma Limited portfolio CI